CUFinder

Leo I Gordon

About Leo I Gordon

Leo I Gordon, With an exceptional h-index of 88 and a recent h-index of 48 (since 2020), a distinguished researcher at North Western University, specializes in the field of lymphoma, Hodgkins, stem cell transplantation, CLL.

His recent articles reflect a diverse array of research interests and contributions to the field:

Lisocabtagene maraleucel in relapsed/refractory mantle cell lymphoma: Primary analysis of the mantle cell lymphoma cohort from TRANSCEND NHL 001, a phase I multicenter seamless …

Impact of Race and Social Determinants of Health on Outcomes in Patients with Aggressive B-cell nHL Treated with CAR-T

Subsequent Malignant Neoplasms in Patients Previously Treated with Anti-CD19 CAR T-Cell Therapy

Lisocabtagene Maraleucel (liso-cel) As Second-Line Therapy for R/R Large B-Cell Lymphoma in Patients Not Intended for Hematopoietic Stem Cell Transplantation (HSCT): Final …

Lisocabtagene Maraleucel (liso-cel) in Patients (Pt) with R/R MCL: Subgroup Analyses in Pts with High-Risk Disease Features from the MCL Cohort of the TRANSCEND NHL 001

Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001

Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemia

Checkpoint inhibitor myocarditis with preceding immunosuppression and tolerance of sequential anthracycline therapy

Leo I Gordon Information

University

Position

Feinberg School of Medicine

Citations(all)

32717

Citations(since 2020)

11169

Cited By

25218

hIndex(all)

88

hIndex(since 2020)

48

i10Index(all)

307

i10Index(since 2020)

166

Email

University Profile Page

Google Scholar

Leo I Gordon Skills & Research Interests

lymphoma

Hodgkins

stem cell transplantation

CLL

Top articles of Leo I Gordon

Lisocabtagene maraleucel in relapsed/refractory mantle cell lymphoma: Primary analysis of the mantle cell lymphoma cohort from TRANSCEND NHL 001, a phase I multicenter seamless …

Journal of Clinical Oncology

2024/4/1

Michael Wang
Michael Wang

H-Index: 9

Leo I Gordon
Leo I Gordon

H-Index: 49

Manali Kamdar
Manali Kamdar

H-Index: 16

Amitkumar Mehta
Amitkumar Mehta

H-Index: 41

Impact of Race and Social Determinants of Health on Outcomes in Patients with Aggressive B-cell nHL Treated with CAR-T

Blood

2022/11/15

Ishan Roy
Ishan Roy

H-Index: 8

Joanna Zurko
Joanna Zurko

H-Index: 5

Robert Ferdman
Robert Ferdman

H-Index: 38

Rahul Bhansali
Rahul Bhansali

H-Index: 2

Shuo Ma
Shuo Ma

H-Index: 15

Leo I Gordon
Leo I Gordon

H-Index: 49

Subsequent Malignant Neoplasms in Patients Previously Treated with Anti-CD19 CAR T-Cell Therapy

Blood Advances

2024/3/18

Adam Yuh Lin
Adam Yuh Lin

H-Index: 12

Shuo Ma
Shuo Ma

H-Index: 15

Ishan Roy
Ishan Roy

H-Index: 8

Leo I Gordon
Leo I Gordon

H-Index: 49

Lisocabtagene Maraleucel (liso-cel) As Second-Line Therapy for R/R Large B-Cell Lymphoma in Patients Not Intended for Hematopoietic Stem Cell Transplantation (HSCT): Final …

Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy

2024/2/1

Mehdi Hamadani
Mehdi Hamadani

H-Index: 40

Nina Wagner-Johnston
Nina Wagner-Johnston

H-Index: 36

Zhi Yang
Zhi Yang

H-Index: 7

Leo I Gordon
Leo I Gordon

H-Index: 49

Lisocabtagene Maraleucel (liso-cel) in Patients (Pt) with R/R MCL: Subgroup Analyses in Pts with High-Risk Disease Features from the MCL Cohort of the TRANSCEND NHL 001

Transplantation and Cellular Therapy

2024/2/1

Leo I Gordon
Leo I Gordon

H-Index: 49

Manali Kamdar
Manali Kamdar

H-Index: 16

Amitkumar Mehta
Amitkumar Mehta

H-Index: 41

Michael Wang
Michael Wang

H-Index: 9

Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001

Blood

2024/2/1

Leo I Gordon
Leo I Gordon

H-Index: 49

Michael Wang
Michael Wang

H-Index: 9

Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemia

Blood Advances

2024/1/23

Shuo Ma
Shuo Ma

H-Index: 15

Checkpoint inhibitor myocarditis with preceding immunosuppression and tolerance of sequential anthracycline therapy

BMJ Case Reports CP

2024/1/1

Leo I Gordon
Leo I Gordon

H-Index: 49

A phase 1-2 trial of DA-EPOCH-R plus ixazomib for MYC-aberrant lymphoid malignancies: the DACIPHOR regimen

Blood Advances

2024/4/9

Mehdi Hamadani
Mehdi Hamadani

H-Index: 40

Shuo Ma
Shuo Ma

H-Index: 15

Valerie Nelson
Valerie Nelson

H-Index: 12

Andreas Klein
Andreas Klein

H-Index: 37

Irene Helenowski
Irene Helenowski

H-Index: 31

Xinlei Mi
Xinlei Mi

H-Index: 5

GLOBAL LONGITUDINAL STRAIN IS ASSOCIATED WITH CARDIOVASCULAR ADVERSE EVENTS IN DIFFUSE LARGE B CELL LYMPHOMA PATIENTS RECEIVING CHIMERIC ANTIGEN RECEPTOR T CELL THERAPIES

Journal of the American College of Cardiology

2024/4/2

Shuo Ma
Shuo Ma

H-Index: 15

TIMELINE OF THE DEVELOPMENT OF CARDIOVASCULAR ADVERSE EVENTS FOLLOWING TREATMENT WITH CHIMERIC ANTIGEN RECEPTOR T CELL THERAPIES

Journal of the American College of Cardiology

2024/4/2

Nikita Patel
Nikita Patel

H-Index: 1

Shuo Ma
Shuo Ma

H-Index: 15

Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study

Journal of Hematology & Oncology

2023/11/9

Lei Feng
Lei Feng

H-Index: 9

Harsh Shah
Harsh Shah

H-Index: 6

Thomas Ollila
Thomas Ollila

H-Index: 4

Joanna Zurko
Joanna Zurko

H-Index: 5

Leo I Gordon
Leo I Gordon

H-Index: 49

Shuo Ma
Shuo Ma

H-Index: 15

Romil Patel
Romil Patel

H-Index: 3

NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023: Featured Updates to the NCCN Guidelines

Journal of the National Comprehensive Cancer Network

2023/11/1

Leo I Gordon
Leo I Gordon

H-Index: 49

Mayur Narkhede
Mayur Narkhede

H-Index: 5

Rachel Rabinovitch
Rachel Rabinovitch

H-Index: 33

Praveen Ramakrishnan
Praveen Ramakrishnan

H-Index: 3

Erin Reid
Erin Reid

H-Index: 11

Jakub Svoboda
Jakub Svoboda

H-Index: 26

Multicenter phase 2 study of romidepsin plus lenalidomide for previously untreated peripheral T-cell lymphoma

Blood Advances

2023/10/10

Xinlei Mi
Xinlei Mi

H-Index: 5

Leo I Gordon
Leo I Gordon

H-Index: 49

Humoral Immunity After COVID-19 Vaccination in Chronic Lymphocytic Leukemia and Other Indolent Lymphomas: A Single-Center Observational Study

The Oncologist

2023/10/1

Xinlei Mi
Xinlei Mi

H-Index: 5

Leo I Gordon
Leo I Gordon

H-Index: 49

Shuo Ma
Shuo Ma

H-Index: 15

MCL-096 Lisocabtagene Maraleucel (Liso-Cel) in R/R MCL: Primary Analysis Results From the MCL Cohort of the Single-Arm, Multicenter, Phase I Seamless Design TRANSCEND NHL 001 Study

Clinical Lymphoma Myeloma and Leukemia

2023/9/1

Leo I Gordon
Leo I Gordon

H-Index: 49

Manali Kamdar
Manali Kamdar

H-Index: 16

Amitkumar Mehta
Amitkumar Mehta

H-Index: 41

Michael Wang
Michael Wang

H-Index: 9

Phase 2 trial of umbralisib, ublituximab, and venetoclax in patients with relapsed/refractory mantle cell lymphoma

Leukemia & Lymphoma

2023/7/29

Leo I Gordon
Leo I Gordon

H-Index: 49

Shuo Ma
Shuo Ma

H-Index: 15

Discovering the fibroblastic reticular cell in the immune tumor microenvironment in lymphoma

The Journal of clinical investigation

2023/7/3

Adam Yuh Lin
Adam Yuh Lin

H-Index: 12

Leo I Gordon
Leo I Gordon

H-Index: 49

Peri–CAR-T practice patterns and survival predictors for all CAR-T patients and post–CAR-T failure in aggressive B-NHL

Blood Advances

2023/6/27

Joanna Zurko
Joanna Zurko

H-Index: 5

Thomas Ollila
Thomas Ollila

H-Index: 4

Ishan Roy
Ishan Roy

H-Index: 8

Robert Ferdman
Robert Ferdman

H-Index: 38

Shuo Ma
Shuo Ma

H-Index: 15

Leo I Gordon
Leo I Gordon

H-Index: 49

Sequential pembrolizumab and AVD are highly effective at any PD-L1 expression level in untreated Hodgkin lymphoma

Blood advances

2023/6/27

Xinyan Lu
Xinyan Lu

H-Index: 4

Qing Chen
Qing Chen

H-Index: 7

Leo I Gordon
Leo I Gordon

H-Index: 49

See List of Professors in Leo I Gordon University(North Western University)